Literature DB >> 3489121

Protection of adult BALB/c mice against MOPC 315 myeloma by neonatal administration of monoclonal anti-idiotypic antibody to MOPC 315 IgA.

R Gorczynski, R Baumal, M Boulanger, A Marks.   

Abstract

Ascitic fluid containing monoclonal anti-idiotypic antibody (AIA) to MOPC 315 IgA was administered to newborn BALB/c mice, and the mice were challenged in adulthood with IgA-producing MOPC 315 myeloma cells. Administration of AIA D10 (a hybrid molecule containing IgG1 and IgG2a heavy chains), G3 (IgG2b), and A2 (IgG1), all of which reacted with MOPC 315 cells in a cell-binding radioimmunoassay, prolonged survival and reduced the percentage of IgA-producing spleen fragments derived from mice challenged with MOPC 315 myeloma cells, but not with cells of a related IgA-producing myeloma, MOPC 460. Reduction in the percentage of IgA-producing spleen fragments was prevented by treatment of spleen cells prior to culture with anti-Thy 1.2 antibody and complement. Administration of AIA F1 (IgG2a), which did not react with MOPC 315 cells in vitro, or of an antibody with no AIA activity did not produce a similar protection. These results suggest that administration of AIA to MOPC 315 IgA to neonatal BALB/c mice induces idiotype-specific T-lymphocytes that protect these mice against a challenge with MOPC 315 myeloma cells in adulthood.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489121     DOI: 10.1093/jnci/77.3.801

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Effect of neonatal injection with antibodies to Leishmania mexicana on its growth in adult infected mice.

Authors:  R M Gorczynski
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

2.  Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections.

Authors:  M A Montesano; D G Colley; S Eloi-Santos; G L Freeman; W E Secor
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.